What is the clinical evidence from this study?

Study design: Other. Population: Immunogenic tumors. Intervention: Captopril. Primary outcome: Tumor take and survival.

What question did this study set out to answer?

This study aims to assess the effects of captopril on the growth of immunogenic tumors in immunocompetent mice.

July 1, 2006Clinical Cancer Research

Captopril, an Angiotensin-Converting Enzyme Inhibitor, Promotes Growth of Immunogenic Tumors in Mice

View Full Paper

Ask AI

Bookmark

Key result

Captopril decreased survival of immunocompetent mice bearing RenCa tumors and promoted formation of immunogenic MethA sarcoma tumors, suggesting tumor-promoting properties via immunomodulation.

Authors

PWPiotr J. WysockiJagiellonian University EKEliza KwiatkowskaGreater Poland Cancer Center UKUrszula KazimierczakPoznan University of Medical Sciences

Discussion

Member takes

Implication

Captopril promotes immunogenic tumor growth in immunocompetent models; challenges prior data from immunocompromised settings and leaves clinical relevance open.

Key Points

This study aims to assess the effects of captopril on the growth of immunogenic tumors in immunocompetent mice.
Used murine tumor models, including RenCa and MethA tumors.
Evaluated tumor take and survival in immunocompetent versus immunocompromised mice.
Assessed immune responses with model antigens and analyzed immune cell infiltration.
Captopril decreased survival of RenCa-bearing immunocompetent mice in a dose-dependent manner.
It promoted the formation of immunogenic MethA tumors but not nonimmunogenic melanoma cells.
Captopril treatment did not affect tumor formation or survival in immunocompromised mice.

PICO

Population

Murine tumor models using immunocompetent and immunocompromised mice to evaluate the effect of captopril on tumor take and survival.

Intervention / Comparator

Captopril

Primary Outcome

Tumor take and survival

Cite This Study

Wysocki et al. (2006) studied Immunogenic tumors. Captopril was evaluated on Tumor take and survival. Captopril decreased survival of immunocompetent mice bearing RenCa tumors and promoted formation of immunogenic MethA sarcoma tumors, suggesting tumor-promoting properties via immunomodulation.

synapsesocial.com/papers/6a5e79f467fd328bf6efebfe https://doi.org/10.1158/1078-0432.ccr-05-2489

View Full Paper

Ask AI

Bookmark

Implication

Captopril promotes immunogenic tumor growth in immunocompetent models; challenges prior data from immunocompromised settings and leaves clinical relevance open.

Captopril, an Angiotensin-Converting Enzyme Inhibitor, Promotes Growth of Immunogenic Tumors in Mice

Discussion

Member takes

Implication

Key Points

PICO

Cite This Study

Captopril, an Angiotensin-Converting Enzyme Inhibitor, Promotes Growth of Immunogenic Tumors in Mice

Discussion

Member takes

Implication

Key Points

PICO

Cite This Study

Also Consider

Also Consider